Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration

Ching-Hon Pui; Jun J Yang; Stephen P Hunger; Rob Pieters; Martin Schrappe; Andrea Biondi; Ajay Vora; André Baruchel; Lewis B Silverman; Kjeld Schmiegelow; Gabriele Escherich; Keizo Horibe; Yves C M Benoit; Shai Izraeli; Allen Eng Juh Yeoh; Der-Cherng Liang; James R Downing; William E Evans; Mary V Relling; Charles G Mullighan

doi:10.1200/JCO.2014.59.1636

Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration

Ching-Hon Pui, Jun J Yang, Stephen P Hunger, Rob Pieters, Martin Schrappe, Andrea Biondi, Ajay Vora, André Baruchel, Lewis B Silverman, Kjeld Schmiegelow, Gabriele Escherich, Keizo Horibe, Yves C M Benoit, Shai Izraeli, Allen Eng Juh Yeoh, Der-Cherng Liang, James R Downing, William E Evans, Mary V Relling, Charles G Mullighan

Institut for Klinisk Medicin

408 Citationer (Scopus)

Abstract

PURPOSE: To review the impact of collaborative studies on advances in the biology and treatment of acute lymphoblastic leukemia (ALL) in children and adolescents.

METHODS: A review of English literature on childhood ALL focusing on collaborative studies was performed. The resulting article was reviewed and revised by the committee chairs of the major ALL study groups.

RESULTS: With long-term survival rates for ALL approaching 90% and the advent of high-resolution genome-wide analyses, several international study groups or consortia were established to conduct collaborative research to further improve outcome. As a result, treatment strategies have been improved for several subtypes of ALL, such as infant, MLL-rearranged, Philadelphia chromosome-positive, and Philadelphia chromosome-like ALL. Many recurrent genetic abnormalities that respond to tyrosine kinase inhibitors and multiple genetic determinants of drug resistance and toxicities have been identified to help develop targeted therapy. Several genetic polymorphisms have been recognized that show susceptibility to developing ALL and that help explain the racial/ethnic differences in the incidence of ALL.

CONCLUSION: The information gained from collaborative studies has helped decipher the heterogeneity of ALL to help improve personalized treatment, which will further advance the current high cure rate and the quality of life for children and adolescents with ALL.

Originalsprog	Engelsk
Tidsskrift	Journal of Clinical Oncology
Vol/bind	33
Udgave nummer	27
Sider (fra-til)	2938-48
Antal sider	11
ISSN	0732-183X
DOI	https://doi.org/10.1200/JCO.2014.59.1636
Status	Udgivet - 20 sep. 2015

Adgang til dokumentet

10.1200/JCO.2014.59.1636

Citationsformater

Pui, C-H., Yang, J. J., Hunger, S. P., Pieters, R., Schrappe, M., Biondi, A., Vora, A., Baruchel, A., Silverman, L. B., Schmiegelow, K., Escherich, G., Horibe, K., Benoit, Y. C. M., Izraeli, S., Yeoh, A. E. J., Liang, D-C., Downing, J. R., Evans, W. E., Relling, M. V., & Mullighan, C. G. (2015). Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration. Journal of Clinical Oncology, 33(27), 2938-48. https://doi.org/10.1200/JCO.2014.59.1636

Pui, C-H, Yang, JJ, Hunger, SP, Pieters, R, Schrappe, M, Biondi, A, Vora, A, Baruchel, A, Silverman, LB, Schmiegelow, K, Escherich, G, Horibe, K, Benoit, YCM, Izraeli, S, Yeoh, AEJ, Liang, D-C, Downing, JR, Evans, WE, Relling, MV & Mullighan, CG 2015, 'Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration', Journal of Clinical Oncology, bind 33, nr. 27, s. 2938-48. https://doi.org/10.1200/JCO.2014.59.1636

@article{ce29cb03245344ca8a3469e445ba2104,

title = "Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration",

abstract = "PURPOSE: To review the impact of collaborative studies on advances in the biology and treatment of acute lymphoblastic leukemia (ALL) in children and adolescents.METHODS: A review of English literature on childhood ALL focusing on collaborative studies was performed. The resulting article was reviewed and revised by the committee chairs of the major ALL study groups.RESULTS: With long-term survival rates for ALL approaching 90% and the advent of high-resolution genome-wide analyses, several international study groups or consortia were established to conduct collaborative research to further improve outcome. As a result, treatment strategies have been improved for several subtypes of ALL, such as infant, MLL-rearranged, Philadelphia chromosome-positive, and Philadelphia chromosome-like ALL. Many recurrent genetic abnormalities that respond to tyrosine kinase inhibitors and multiple genetic determinants of drug resistance and toxicities have been identified to help develop targeted therapy. Several genetic polymorphisms have been recognized that show susceptibility to developing ALL and that help explain the racial/ethnic differences in the incidence of ALL.CONCLUSION: The information gained from collaborative studies has helped decipher the heterogeneity of ALL to help improve personalized treatment, which will further advance the current high cure rate and the quality of life for children and adolescents with ALL.",

keywords = "Adolescent, Age of Onset, Biomarkers, Tumor, Child, Child, Preschool, Cooperative Behavior, Diffusion of Innovation, Genetic Predisposition to Disease, Genetic Testing, History, 20th Century, History, 21st Century, Humans, Infant, Infant, Newborn, Interdisciplinary Communication, International Cooperation, Medical Oncology, Pediatrics, Phenotype, Precision Medicine, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Predictive Value of Tests, Survivors, Time Factors, Treatment Outcome",

author = "Ching-Hon Pui and Yang, {Jun J} and Hunger, {Stephen P} and Rob Pieters and Martin Schrappe and Andrea Biondi and Ajay Vora and Andr{\'e} Baruchel and Silverman, {Lewis B} and Kjeld Schmiegelow and Gabriele Escherich and Keizo Horibe and Benoit, {Yves C M} and Shai Izraeli and Yeoh, {Allen Eng Juh} and Der-Cherng Liang and Downing, {James R} and Evans, {William E} and Relling, {Mary V} and Mullighan, {Charles G}",

note = "{\textcopyright} 2015 by American Society of Clinical Oncology.",

year = "2015",

month = sep,

day = "20",

doi = "10.1200/JCO.2014.59.1636",

language = "English",

volume = "33",

pages = "2938--48",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "American Society of Clinical Oncology",

number = "27",

}

TY - JOUR

T1 - Childhood Acute Lymphoblastic Leukemia

T2 - Progress Through Collaboration

AU - Pui, Ching-Hon

AU - Yang, Jun J

AU - Hunger, Stephen P

AU - Pieters, Rob

AU - Schrappe, Martin

AU - Biondi, Andrea

AU - Vora, Ajay

AU - Baruchel, André

AU - Silverman, Lewis B

AU - Schmiegelow, Kjeld

AU - Escherich, Gabriele

AU - Horibe, Keizo

AU - Benoit, Yves C M

AU - Izraeli, Shai

AU - Yeoh, Allen Eng Juh

AU - Liang, Der-Cherng

AU - Downing, James R

AU - Evans, William E

AU - Relling, Mary V

AU - Mullighan, Charles G

PY - 2015/9/20

Y1 - 2015/9/20

N2 - PURPOSE: To review the impact of collaborative studies on advances in the biology and treatment of acute lymphoblastic leukemia (ALL) in children and adolescents.METHODS: A review of English literature on childhood ALL focusing on collaborative studies was performed. The resulting article was reviewed and revised by the committee chairs of the major ALL study groups.RESULTS: With long-term survival rates for ALL approaching 90% and the advent of high-resolution genome-wide analyses, several international study groups or consortia were established to conduct collaborative research to further improve outcome. As a result, treatment strategies have been improved for several subtypes of ALL, such as infant, MLL-rearranged, Philadelphia chromosome-positive, and Philadelphia chromosome-like ALL. Many recurrent genetic abnormalities that respond to tyrosine kinase inhibitors and multiple genetic determinants of drug resistance and toxicities have been identified to help develop targeted therapy. Several genetic polymorphisms have been recognized that show susceptibility to developing ALL and that help explain the racial/ethnic differences in the incidence of ALL.CONCLUSION: The information gained from collaborative studies has helped decipher the heterogeneity of ALL to help improve personalized treatment, which will further advance the current high cure rate and the quality of life for children and adolescents with ALL.

AB - PURPOSE: To review the impact of collaborative studies on advances in the biology and treatment of acute lymphoblastic leukemia (ALL) in children and adolescents.METHODS: A review of English literature on childhood ALL focusing on collaborative studies was performed. The resulting article was reviewed and revised by the committee chairs of the major ALL study groups.RESULTS: With long-term survival rates for ALL approaching 90% and the advent of high-resolution genome-wide analyses, several international study groups or consortia were established to conduct collaborative research to further improve outcome. As a result, treatment strategies have been improved for several subtypes of ALL, such as infant, MLL-rearranged, Philadelphia chromosome-positive, and Philadelphia chromosome-like ALL. Many recurrent genetic abnormalities that respond to tyrosine kinase inhibitors and multiple genetic determinants of drug resistance and toxicities have been identified to help develop targeted therapy. Several genetic polymorphisms have been recognized that show susceptibility to developing ALL and that help explain the racial/ethnic differences in the incidence of ALL.CONCLUSION: The information gained from collaborative studies has helped decipher the heterogeneity of ALL to help improve personalized treatment, which will further advance the current high cure rate and the quality of life for children and adolescents with ALL.

KW - Adolescent

KW - Age of Onset

KW - Biomarkers, Tumor

KW - Child

KW - Child, Preschool

KW - Cooperative Behavior

KW - Diffusion of Innovation

KW - Genetic Predisposition to Disease

KW - Genetic Testing

KW - History, 20th Century

KW - History, 21st Century

KW - Humans

KW - Infant

KW - Infant, Newborn

KW - Interdisciplinary Communication

KW - International Cooperation

KW - Medical Oncology

KW - Pediatrics

KW - Phenotype

KW - Precision Medicine

KW - Precursor Cell Lymphoblastic Leukemia-Lymphoma

KW - Predictive Value of Tests

KW - Survivors

KW - Time Factors

KW - Treatment Outcome

U2 - 10.1200/JCO.2014.59.1636

DO - 10.1200/JCO.2014.59.1636

M3 - Review

C2 - 26304874

SN - 0732-183X

VL - 33

SP - 2938

EP - 2948

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 27

ER -

Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater